Literature DB >> 15806161

Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia.

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani1, Dominik Spensberger, Yvonne de Knegt, Michelle Tang, Bob Löwenberg, Ruud Delwel.   

Abstract

ETV6 (ets translocation variant gene 6) TEL (translocation ets leukemia), encoding a transcriptional repressor, is involved in various translocations associated with human malignancies. Strikingly, the nonrearranged ETV6 allele is often deleted or inactivated in cells harboring these translocations. Although ETV6 translocations are infrequent in acute myeloid leukemia (AML), mutations or deregulated expression of ETV6 may contribute to leukemogenesis. To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. Furthermore, we studied protein expression in 77 patients using two ETV6-specific antibodies. Five somatic heterozygous mutations were detected, which affected either the homodimerization- or the DNA-binding domain of ETV6. The proteins translated from the cDNAs of these mutants were unable to repress transcription and showed dominant-negative effects. In addition, we demonstrate that one-third of AML patients have deficient ETV6 protein expression, which is not related to ETV6 mRNA expression levels. In conclusion, we demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought. Additional comprehensive studies are required to define the clinical consequence of ETV6 loss of function in AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806161     DOI: 10.1038/sj.onc.1208588

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.

Authors:  D M Ross; H K Altamura; C N Hahn; M Nicola; A L Yeoman; M R Holloway; J Geoghegan; J Feng; A W Schreiber; S Branford; S Moore; H S Scott
Journal:  Leukemia       Date:  2015-10-27       Impact factor: 11.528

Review 2.  ETV6 in hematopoiesis and leukemia predisposition.

Authors:  Hanno Hock; Akiko Shimamura
Journal:  Semin Hematol       Date:  2017-04-07       Impact factor: 3.851

Review 3.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

4.  ETV6 mutation in a cohort of 970 patients with hematologic malignancies.

Authors:  Qinrong Wang; Shasha Dong; Hong Yao; Lijun Wen; Huiying Qiu; Llili Qin; Liang Ma; Suning Chen
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

5.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

6.  Low-level expression of ETV6/TEL in patients with Myelodysplastic syndrome.

Authors:  Tetsuya Yamagata; Yuka Nakamura; Kinuko Mitani
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors:  Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 8.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

9.  Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function.

Authors:  M Guy Roukens; Mariam Alloul-Ramdhani; Alfred C O Vertegaal; Zeinab Anvarian; Crina I A Balog; André M Deelder; Paul J Hensbergen; David A Baker
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

10.  Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination.

Authors:  M Guy Roukens; Mariam Alloul-Ramdhani; Setareh Moghadasi; Marjolein Op den Brouw; David A Baker
Journal:  Mol Cell Biol       Date:  2008-04-21       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.